Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	162
Overall Study	STARTED	Avanafil 50 mg	161
Overall Study	STARTED	Avanafil 100 mg	161
Overall Study	STARTED	Avanafil 200 mg	162
Overall Study	COMPLETED	Placebo	137
Overall Study	COMPLETED	Avanafil 50 mg	131
Overall Study	COMPLETED	Avanafil 100 mg	141
Overall Study	COMPLETED	Avanafil 200 mg	141
Overall Study	NOT COMPLETED	Placebo	25
Overall Study	NOT COMPLETED	Avanafil 50 mg	30
Overall Study	NOT COMPLETED	Avanafil 100 mg	20
Overall Study	NOT COMPLETED	Avanafil 200 mg	21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00790751/flow